{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T06:16:50Z","timestamp":1771049810516,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.survophthal.2021.08.003","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T21:45:28Z","timestamp":1630532728000},"page":"697-711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Ocriplasmin for treatment of vitreomacular traction and macular hole: A systematic literature review and individual participant data meta-analysis of randomized, controlled, double-masked trials"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-1555","authenticated-orcid":false,"given":"Timothy L.","family":"Jackson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Haller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9120-4102","authenticated-orcid":false,"given":"Koenraad H.","family":"Blot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0462-3638","authenticated-orcid":false,"given":"Luc","family":"Duchateau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-0330","authenticated-orcid":false,"given":"Benedicte","family":"Lescrauwaet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2021.08.003_bib0001","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/IAE.0000000000001536","article-title":"Evaluation of Full-Field Electroretinogram Reductions After Ocriplasmin Treatment: Results of the OASIS Trial ERG Substudy","volume":"38","author":"Birch","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0002","unstructured":"ClinicalTrials.gov [Internet]: Bethesda (MD): National Library of Medicine (US). Identifier NCT01889251. A Phase III study of A01016 in subjects with symptomatic vitreomacular adhesion. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/nct01889251, 2013"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0003","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ajo.2015.03.017","article-title":"Characterization of Anatomic and Visual Function Outcomes in Patients With Full-Thickness Macular Hole in Ocriplasmin Phase 3 Trials","volume":"160","author":"Dugel","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0004","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.ophtha.2016.06.043","article-title":"Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial","volume":"123","author":"Dugel","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0002-9394(82)90197-0","article-title":"New visual acuity charts for clinical research","volume":"94","author":"Ferris","year":"1982","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0006","doi-asserted-by":"crossref","first-page":"P152","DOI":"10.1016\/j.ophtha.2015.10.048","article-title":"Idiopathic Epiretinal Membrane and Vitreomacular Traction Preferred Practice Pattern((R)) Guidelines","volume":"123","author":"Folk","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0007","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/IAE.0000000000000508","article-title":"Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion\/vitreomacular traction, including when associated with macular hole","volume":"35","author":"Gandorfer","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ophtha.2014.07.045","article-title":"Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials","volume":"122","author":"Haller","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0009","unstructured":"Higgins JP, Sterne J, Savovi\u0107 J, et\u00a0al: A revised tool for assessing risk of bias in randomized trials, in Chandler J MJ, Boutron I, Welch V (ed): Cochrane Methods, 2016"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0010","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3928\/23258160-20160808-04","article-title":"Baseline Predictors of Vitreomacular Adhesion\/Traction Resolution Following an Intravitreal Injection of Ocriplasmin","volume":"47","author":"Jackson","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"S256","key":"10.1016\/j.survophthal.2021.08.003_bib0011","doi-asserted-by":"crossref","DOI":"10.1111\/j.1755-3768.2016.0592","article-title":"Visual function response to ocriplasmin for the treatment of vitreomacular traction: results from the oasis study","volume":"94","author":"Jackson","year":"2016","journal-title":"Acta Ophthalmologica"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0012","doi-asserted-by":"crossref","first-page":"e740","DOI":"10.1111\/aos.13369","article-title":"Visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole","volume":"95","author":"Jackson","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0013","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ajo.2009.11.022","article-title":"Posterior vitreous detachment: evolution and complications of its early stages","volume":"149","author":"Johnson","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0014","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/IAE.0000000000000448","article-title":"Safety profile of ocriplasmin for the pharmacologic treatment of symptomatic vitreomacular adhesion\/traction","volume":"35","author":"Kaiser","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0015","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1167\/iovs.17-22363","article-title":"Visual Function Response to Ocriplasmin for the Treatment of Vitreomacular Traction and Macular Hole: The OASIS Study","volume":"58","author":"Lescrauwaet","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0016","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.oret.2016.10.018","article-title":"Macula Society collaborative retrospective study of ocriplasmin for symptomatic vitreomacular adhesion","volume":"1","author":"Lim","year":"2017","journal-title":"Ophthalmology Retina"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0017","doi-asserted-by":"crossref","first-page":"27","DOI":"10.47102\/annals-acadmedsg.V33N1p27","article-title":"Prevalence of myopia in Taiwanese schoolchildren: 1983 to 2000","volume":"33","author":"Lin","year":"2004","journal-title":"Ann Acad Med Singap"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0018","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/bjo.2009.157727","article-title":"The epidemiology of rhegmatogenous retinal detachment: geographical variation and clinical associations","volume":"94","author":"Mitry","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0019","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"41","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011874.pub2","article-title":"Ocriplasmin for symptomatic vitreomacular adhesion","author":"Neffendorf","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0021","first-page":"749","article-title":"The Eye Disease Case-Control Study Group","volume":"137","year":"1993","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0022","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.2041-210x.2012.00250.x","article-title":"Review of alternative approaches to calculation of a confidence interval for the odds ratio of a 2\u00a0\u00d7\u00a02 contingency table","volume":"4","author":"Ruxton","year":"2013","journal-title":"Meth in Ecol and Evol"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0023","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bjo.2009.157313","article-title":"Vitreous: the resplendent enigma","volume":"93","author":"Sebag","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0024","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/IAE.0b013e3181e0970a","article-title":"Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial)","volume":"30","author":"Stalmans","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0025","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1056\/NEJMoa1110823","article-title":"Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes","volume":"367","author":"Stalmans","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0026","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00417-016-3294-1","article-title":"A retrospective cohort study in patients with tractional diseases of the vitreomacular interface (ReCoVit)","volume":"254","author":"Stalmans","year":"2016","journal-title":"Graefe's Archive for Clin and Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0027","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0163278702025001006","article-title":"To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data","volume":"25","author":"Stewart","year":"2002","journal-title":"Eval Health Prof"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0028","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.oret.2018.05.004","article-title":"Subfoveal Lucency after Treatment of Vitreomacular Traction without Macular Hole in the Phase 3 Trials of Ocriplasmin Vitreolysis","volume":"3","author":"Thomas","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001855","article-title":"Individual Participant Data (IPD) Meta-analyses of Randomised Controlled Trials: Guidance on Their Use","volume":"12","author":"Tierney","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0030","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1001\/jamaophthalmol.2015.1746","article-title":"Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials","volume":"133","author":"Varma","year":"2015","journal-title":"JAMA Ophthalmology"},{"key":"10.1016\/j.survophthal.2021.08.003_bib0031","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/eye.2008.184","article-title":"Changes of the ocular refraction among freshmen in National Taiwan University between 1988 and 2005","volume":"23","author":"Wang","year":"2009","journal-title":"Eye (Lond)"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625721001740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625721001740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:52:11Z","timestamp":1758541931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625721001740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0039625721001740"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2021.08.003","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocriplasmin for treatment of vitreomacular traction and macular hole: A systematic literature review and individual participant data meta-analysis of randomized, controlled, double-masked trials","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2021.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}